Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | RAF1 | P04049 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.55 |
| ▸ | CDK8 | P49336 | 3/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18053822 | 0.85 | KDR (0.67) | KDRKMT2ATRPV1CA7CA9 | |
| SCHEMBL30481106 | 0.85 | KDR (0.67) | KDRKMT2ATRPV1CA7CA9 | |
| SCHEMBL30481107 | 0.85 | KDR (0.67) | KDRKMT2ATRPV1CA7CA9 | |
| SCHEMBL30481102 | 0.84 | KDR (0.65) | KDRBRAFRAF1TRPV1CA7 | |
| SCHEMBL20481323 | 0.84 | KDR (0.65) | KDRBRAFRAF1TRPV1CA7 | |
| SCHEMBL13524613 | 0.83 | GSK3B (0.55) | KDRKMT2ABRAFMAPK14MEN1 | |
| SCHEMBL118026 | 0.81 | KDR (1.00) | KDRTRPV1CA7CA9CA1 | |
| SCHEMBL29364392 | 0.81 | KDR (1.00) | KDRTRPV1CA7CA9CA1 | |
| SCHEMBL22125332 | 0.80 | KDR (0.76) | KDRKMT2ABRAFMAPK14RAF1 | |
| SCHEMBL23258570 | 0.79 | KDR (0.55) | KDRTRPV1CA7CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDR 1402/4885KMT2A 501/4885NPC1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.